Cargando…
A MCP1 fusokine with CCR2-specific tumoricidal activity
BACKGROUND: The CCL2 chemokine is involved in promoting cancer angiogenesis, proliferation and metastasis by malignancies that express CCR2 receptor. Thus the CCL2/CCR2 axis is an attractive molecular target for anticancer drug development. METHODS: We have generated a novel fusion protein using GMC...
Autores principales: | Rafei, Moutih, Deng, Jiusheng, Boivin, Marie-Noëlle, Williams, Patrick, Matulis, Shannon M, Yuan, Shala, Birman, Elena, Forner, Kathy, Yuan, Liangping, Castellino, Craig, Boise, Lawrence H, MacDonald, Tobey J, Galipeau, Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189909/ https://www.ncbi.nlm.nih.gov/pubmed/21943176 http://dx.doi.org/10.1186/1476-4598-10-121 |
Ejemplares similares
-
GIFT4 fusokine converts leukemic B cells into immune helper cells
por: Deng, Jiusheng, et al.
Publicado: (2016) -
FIST, a sword and shield fusokine for cancer immunotherapy
por: Penafuerte, Claudia, et al.
Publicado: (2012) -
Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2
por: Mojumdar, Kamalika, et al.
Publicado: (2014) -
GIFT4-augmented B cells for melanoma immunotherapy
por: Deng, Jiusheng, et al.
Publicado: (2014) -
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
por: Deng, Jiusheng, et al.
Publicado: (2016)